Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Linagliptin

A DPP-4 inhibitor (gliptin) for type 2 diabetes, approved in 2011. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?Unlike the other gliptins it is eliminated mainly through the bile and gut, not the kidneys: no dose change is needed when kidney function is poor.

LinagliptinGo to the active ingredient →
LinagliptinActive ingredientLinagliptinCat. No. P-L066-001CAS 668270-12-0
(S)-LinagliptinPharmacopoeial impurity(S)-LinagliptinCat. No. P-L066-002CAS 668270-11-9
Linagliptin-d3Isotopically labelledLinagliptin-d3Cat. No. P-L066-009CAS 1398044-48-8
Linagliptin-d4Isotopically labelledLinagliptin-d4Cat. No. P-L066-010CAS 2140263-92-7

EDQM standards 7

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.